Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1112

Sort by

Sort Order Select

Journal Articles

Sickle marrow: double, double toil and trouble

Mark C. Walters

Blood (2020) 135 (23): 2017–2018.

https://doi.org/10.1182/blood.2020005114

Published: 2020

Journal Articles

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

Denis F. Noubouossie, Michael W. Henderson, Micah Mooberry, Anton Ilich, Patrick Ellsworth, Mark Piegore, Sarah C. Skinner, Rafal Pawlinski, Ian Welsby, Thomas Renné, Maureane Hoffman, Dougald M. Monroe, Nigel S. Key

Blood (2020) 135 (10): 755–765.

https://doi.org/10.1182/blood.2019001643

Published: 2020

Includes: Supplemental data

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

Postpartum Hemorrhage Outcomes in Women with Mild Factor XI Deficiency

Thomas Bogue, BS, Stoeckle James, MD, Jeffrey I. Zwicker, MD

Blood (2019) 134 (Supplement_1): 629.

https://doi.org/10.1182/blood-2019-124759

Published: 2019

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Amer M. Zeidan, MBBS, MHS, Rong Wang, PhD, Xiaoyi Wang, MD MPH, Rory M Shallis, MD, Nikolai A. Podoltsev, MD PhD, Jan Philipp Bewersdorf, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 646.

https://doi.org/10.1182/blood-2019-127398

Published: 2019

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)

Diego Adrianzen Herrera, MD, Kith Pradhan, PhD, Rosebella Snyder, MD, Siddharth Karanth, MBBS, MPH, DrPH, Murali Janakiram, MD MS, Ioannis Mantzaris, MD MS, Santosh Murthy, MD MPH, Amit Verma, MBBS, Aditi Shastri, MD

Blood (2019) 134 (Supplement_1): 336.

https://doi.org/10.1182/blood-2019-123317

Published: 2019

Journal Articles

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Pallavi Mehta, MD DM, Stalin Ramprakash, MD MBBS, C Raghuram, Deepa Trivedi, MD, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, BE, Rajat Kumar Agarwal, BS, Lawrence Faulkner, MD

Blood (2019) 134 (Supplement_1): 4467.

https://doi.org/10.1182/blood-2019-131118

Published: 2019

Journal Articles

Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices

Lisa Y Law, MD, Ryan Stevenson, MD, Gwendolyn Ho, MDMAS, Bijay Nair, MD MPH, Asakura Laura, PharmD, BCOP, BCPS, Antoine Sayegh, MD

Blood (2019) 134 (Supplement_1): 5081.

https://doi.org/10.1182/blood-2019-121816

Published: 2019

Journal Articles

Evolution of Moderate Aplastic Anemia into Subclinical PNH/AA and Successful Treatment with Reduced Intensity Haplo-HSCT: A Pediatric Case Report

Meghana Srinivas, Jennifer Krajewski, MD, Nancy Durning, APN, Melanie Hankewycz, APN, Alfred Gillio, MD

Blood (2019) 134 (Supplement_1): 5027.

https://doi.org/10.1182/blood-2019-130407

Published: 2019

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Emily Bryer, DO, Michael Kallan, MS, Ting-Shaun Chiu, MS, Katerina Scheuba, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 4944.

https://doi.org/10.1182/blood-2019-129316

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Markus M. Mueller, MD, Hans van Remoortel, Patrick Meybohm, Kari Aranko, Mike Murphy, MD, Jeffrey L. Carson, MD, Erhard Seifried, MD PhD

Blood (2019) 134 (Supplement_1): 4982.

https://doi.org/10.1182/blood-2019-130601

Published: 2019

NARROW

Sickle marrow: double, double toil and trouble

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

Postpartum Hemorrhage Outcomes in Women with Mild Factor XI Deficiency

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices

Evolution of Moderate Aplastic Anemia into Subclinical PNH/AA and Successful Treatment with Reduced Intensity Haplo-HSCT: A Pediatric Case Report

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only